Mohamed Sikkander Abdul Razak: A Single Stem Cell Generating 14 Million Tumor-Killing NK Cells
Mohamed Sikkander Abdul Razak, Professor at GKM College of Engineering Technology, shared a post on LinkedIn, adding:
“Recent studies have shown that a single stem cell can generate up to 14 million tumor-killing NK cells, which is a remarkable achievement in cancer immunotherapy.
This breakthrough could lead to more effective treatments for various types of cancer.
The research focuses on engineering early-stage stem cells from cord blood, which has shown promising results in producing large quantities of highly potent NK cells.
These cells can be equipped with CAR (Chimeric Antigen Receptor) technology to target specific cancer cells, offering new hope for cancer patients.
Recent research has shown a significant increase in cancer-fighting NK cells, with an 80% increase in their activities.
This breakthrough is attributed to the use of stem cells from cord blood, which can generate large quantities of highly potent NK cells.
These cells can be engineered with CAR (Chimeric Antigen Receptor) technology to target specific cancer cells, offering new hope for cancer patients.
NK cells play a crucial role in cancer immunotherapy, recognizing and killing tumor cells without prior sensitization.
They exert their effects through various mechanisms, including releasing perforin, granzyme, and secreting cytokines like interferon-γ (IFN-γ).
Key Mechanisms of NK Cell Therapy:
- Direct Killing: NK cells release cytotoxic granules to induce tumor cell death.
- Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC): NK cells mediate ADCC through FcγRIIIa (CD16).
- Cytokine Secretion: NK cells secrete cytokines like IFN-γ to modulate the immune response.
- Clinical Applications:
- Hematologic Malignancies: NK cell therapies have shown response rates ranging from 40% to 80%.
- Solid Tumors: Ongoing research explores NK cell therapy’s potential in treating solid tumors.
Recent advances in CAR-NK cell therapy are revolutionizing cancer treatment, offering safer and more effective options.
This innovative approach harnesses natural killer cells’ innate cytotoxic capabilities, combined with precise genetic engineering, to target cancer cells.
Key Benefits:
- Reduced toxicity: CAR-NK cells exhibit minimal cytokine release syndrome and neurotoxicity compared to CAR-T cells.
- Broad applicability: Effective against hematological malignancies and solid tumors.
- Off-the-shelf potential: Scalable production and cryopreservation enable rapid treatment.
Ongoing Research:
- Optimizing CAR design and combination therapies.
- Enhancing in-vivo persistence and overcoming immunosuppressive tumor microenvironments.
- Exploring applications in autoimmune diseases and infectious diseases.
Notable breakthroughs include:
- Menin inhibitors: Show promise in treating acute myeloid leukemia (AML) and pancreatic cancer.
- Protein degraders: Novel therapies targeting cancer-driving proteins.
- Diet and exercise: Lifestyle interventions improving cancer treatment outcomes.”
Stay updated with Hemostasis Today.
-
Feb 18, 2026, 13:26Jecko Thachil: Are There More Than Anticoagulants for Venous Thromboembolism Prophylaxis?
-
Feb 18, 2026, 12:41Davide Bartoli: The Hidden Cost of Informal Caregiving After Stroke
-
Feb 18, 2026, 12:34Amy Goundry: Which Are The Next Major Advances in Blood and Plasma-Driven Immune Regulation?
-
Feb 18, 2026, 12:26John Monczewski: A Stroke, A Wake‑Up Call, And a Whole Lot of Gratitude
-
Feb 18, 2026, 12:15Danny Hsu: Are Elastic Compression Stockings Ineffective in Preventing Post-Thrombotic Syndrome?
-
Feb 18, 2026, 11:49David Hunt: The Critical Importance of Stroke Awareness
-
Feb 18, 2026, 11:35University of Minnesota Physicians: Christopher Streib Builds A Telestroke Program for Rural Areas in Minnesota
-
Feb 18, 2026, 11:22Michelle Rosenfeld: Mobile Stroke Units in the MENA Region Show How Fast Can Stroke Care Be
-
Feb 18, 2026, 11:15Bader Almohaimeed: Insights On Advancing Stroke Systems of Care